**Supplementary Table 2. Quality assessment based on NOS**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Study design** | **Selection** | | | | **Comparability** | | **Exposure/**  **Outcome** | | | **NOS** | **Quality** |
| Lo (2009) | Cohort | √ | √ | √ |  | √ |  | √ | √ |  | 6 | Moderate |
| Cersosimo (2013) | Case-control | √ | √ | √ |  | √ |  | √ | √ |  | 6 | Moderate |
| Lee (2015) | Cohort | √ | √ | √ | √ | √ |  | √ | √ |  | 7 | High |
| Li (2016) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Fereshtehnejad (2017) | Cohort | √ | √ | √ |  | √ |  | √ | √ |  | 6 | Moderate |
| Malek (2017) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Wang (2017) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |
| Fukuoka (2019) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |
| Paul (2019) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Polychronis (2019) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Umay (2019) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |
| Claus (2020) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Marano (2020) | Cohort | √ | √ | √ |  | √ |  | √ | √ |  | 6 | Moderate |
| Rascol (2020) | Cohort | √ | √ | √ | √ | √ |  | √ | √ |  | 7 | High |
| Schrag (2020) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Wamelen (2020) | Cohort | √ | √ | √ |  | √ |  | √ | √ | √ | 7 | High |
| Cao (2021) | Cohort | √ | √ | √ |  | √ |  | √ |  |  | 5 | Moderate |
| Wang (2021) | Cohort | √ | √ | √ | √ | √ |  | √ | √ | √ | 8 | High |
| Dilmaghani (2022) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |
| Longardner (2022) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |
| Vogel (2022) | Cohort | √ | √ | √ | √ | √ |  | √ |  |  | 6 | Moderate |